<DOC>
	<DOCNO>NCT01188889</DOCNO>
	<brief_summary>Patients participate study diagnosis Chronic Myeloid Leukemia . This study evaluate whether addition investigational drug call RAD001 give together Imatinib good target leukemia stem cell , cause die . Stem cell small population cell , exist primarily within bone marrow , believe responsible ongoing risk disease relapse .</brief_summary>
	<brief_title>RAD001 Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease .</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<criteria>Study subject must least age 18 year old . Study subject must Eastern Cooperative Oncology Group performance status 02 . Study subject must provide sign write informed consent . Study subject must able comply study procedure followup examination . Female study subject : nonfertile ( status post hysterectomy ( removal uterus ) menopausal ( menstrual period ) 24 consecutive month agree use birth control study end last treatment visit . Women childbearing potential must negative serum pregnancy test within 3 day prior administration RAD001 ) . Use single agent prevention pregnancy ( oral , implantable , injectable contraceptive ) may affect medication alter activity cytochrome P450 enzyme , therefore , consider effective participation clinical trial.If ANY chance pregnant occur , must commitment continue abstinence heterosexual intercourse begin TWO method birth control , one highly effective method one additional effective method AT THE SAME TIME . There must least two week since major surgery , completion radiation , completion prior systemic anticancer therapy ( adequately recover acute toxicity prior therapy ) . Study subject must meet following disease criterion : Diagnosis Chronic Myelogenous Leukemia accord World Health Organization . Persistent molecular disease define persistent identification BcrAbl transcript use quantitative RTPCR least 2 occasion least 3 month apart complete minimum 18 month treatment Imatinib 400 mg daily . Achieved complete cytogenetic response . ( This shall measure least one time prior consent participation clinical trial , shall reassess initiation clinical trial . ) Nonhematologic symptom related Imatinib therapy â‰¤ Grade 2 severity least 6 month prior enrollment . Study subject must meet follow organ function criterion : Adequate bone marrow function Adequate renal hepatic function International normalized ration &lt; 1.3 ( &lt; 3 anticoagulant ) Study subject must meet following cardiac function criterion : No history uncontrolled angina , congestive heart failure myocardial infarction within 6 month study entry . If suspected clinical history coronary artery disease , patient must document one follow within 1 year study participation : Left ventricular ejection fraction great 40 % multigated acquisition scan similar radionuclide angiographic scan ; Left ventricular fractional shortening great 22 % echocardiography exam ; LVEF great 40 % echocardiography exam . No history diagnosis suspect congenital QRS complex end T wave electrocardiogram syndrome . No history clinically significant ventricular arrhythmia ( ventricular tachycardia , ventricular fibrillation , Torsades de pointes ) . No history uncontrolled hypertension . Study subject may prior treatment RAD001 , sirolimus , temsirolimus , rapamycin . Study subject may know hypersensitivity RAD001 rapamycin , sirolimus , temsirolimus excipients . Study subject may receive investigational agent receive within 28 day prior first dose study drug . Study subject may psychiatric disorder would interfere consent , study participation , followup . Study subject may history noncompliance medical regimen . Study subject unwilling unable comply protocol eligible participate clinical research trial . Study subject meet follow criterion eligible participate clinical research study : Diagnosis accelerate phase blast phase chronic myeloid leukemia accord World Health Organization criterion . Clinical evidence suggestive central nervous system involvement leukemia unless lumbar puncture confirm absence leukemia cerebrospinal fluid . Prior hematopoietic stem cell transplant . Prior external beam radiation therapy pelvis . Diagnosis another malignancy , unless diseasefree least 3 year follow completion curative intent therapy follow exception : treatment nonmelanoma skin cancer , situ carcinoma , cervical intraepithelial neoplasia , regardless diseasefree duration treatment condition complete . Known chronic condition require treatment systemic steroid another immunosuppressive agent . Systemic fungal , bacterial , viral , infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) . Prior seropositive test human immunodeficiency virus . Uncontrolled diabetes mellitus Impairment gastrointestinal function gastrointestinal disease may significantly alter absorption RAD001 ( e.g. , ulcerative disease , uncontrolled nausea , vomit , diarrhea , malabsorption syndrome small bowel resection ) . Any severe concurrent disease , history serious organ dysfunction disease involve heart , kidney , liver , organ system may place patient undue risk undergo therapy RAD001 include : severely impaired lung function ; liver disease cirrhosis , chronic active hepatitis chronic ; persistent hepatitis ; nonmalignant medical illness uncontrolled whose control may jeopardize treatment study therapy . History significant bleeding disorder unrelated cancer , include : Congenital bleeding disorder ( e.g. , von Willebrand 's disease ) ; Acquired bleed disorder within one year ( e.g. , acquire antifactor VIII antibody ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Chronic Myeloid Leukemia</keyword>
</DOC>